



March 17, 2023

✓ **BSE Limited**

Department of Corporate Services,
P. J. Towers,
Dalal Street,
MUMBAI - 400 001.

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015 ('Listing Regulations').

We are pleased to enclose a Press Release regarding unveiling of results of India's First Digital Therapeutics Study with ACS patients.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**

Encl: a/a

Lupin Digital Health Unveils Results of India's First Digital Therapeutics Study with ACS Patients

*DTx interventions led to 83% patients bringing and maintaining their vitals in normal range
90% Adherence to Medication, Diet and Exercise, and No Re-hospitalisation in First 30 Days*

Chennai, March 17, 2023: Lupin Digital Health (LDH), India's first evidence-based digital therapeutics platform, has unveiled the results of a first-of-its-kind study in India, showing the efficacy of digital therapeutics (DTx) among patients with acute coronary syndrome (ACS) and post-percutaneous coronary interventions. The study findings were presented at the India Live 2023 symposium in Chennai. LDH, a wholly-owned subsidiary of global pharma major Lupin Limited, recently launched its digital therapeutics platform, Lyfe, India's only evidence-based holistic heart care program that significantly reduces the risk of a heart attack and improves the quality of life for cardiac patients.

The one-year-long study was aimed to evaluate the efficacy of LDH's digital therapeutics platform, Lyfe, on cardiovascular events, rehospitalisation, medication adherence, vital sign monitoring, and lifestyle changes among heart patients. During the 90-day interim analysis, patients enrolled in the program demonstrated significant improvement, with 90% adhering to the recommended medication, diet, and exercise regimen. 83.3% of patients maintained their vital signs within the normal range, and no re-hospitalisations occurring during the first 30 days of enrolment.

"As an interventional cardiologist, I am happy to see such positive and promising early results of the study, with more than 90% of patients adhering to the recommended medication, diet, and exercise regimen prescribed by us. By leveraging evidence-based technologies like digital therapeutics, we are revolutionising the way we deliver healthcare to our patients. While this is an excellent start, we intend to undertake extensive clinical studies and foster collaborative efforts among all healthcare stakeholders to establish digital therapeutics in cardiology and unlock their full potential," said **Dr. Abhijeet Palshikar, Interventional Cardiologist, Pune.**

"We are excited to share the positive outcomes of India's first digital therapeutics study. The study's outcomes showcase the effectiveness of our evidence-based and comprehensive heart care program in ensuring high adherence and low re-hospitalisation for patients," said **Sidharth Srinivasan, CEO, Lupin Digital Health.**

"It's gratifying to see that more than 300 leading cardiologists have already enrolled in our Lyfe platform, and we are confident that this number will multiply. We are dedicated to optimising the patient experience through enhancing doctor-patient collaboration, continuously monitoring health



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

vitals, increasing patient awareness, and improving therapy adherence, all leading to better outcomes,” **he further added.**

The study results indicate that digital therapeutics programs will have a crucial role in patient care across the cardiology continuum, powered by technology. These results showcase a promising future for remote patient care in cardiology, utilising the potential of digital health to improve patients' heart health.

About Lupin Digital Health

Lupin Digital Health is a fully owned subsidiary of Lupin Limited, a global pharmaceutical company, focused on developing innovative digital health solutions to address unmet patient needs. The company's flagship product, Lyfe, is a comprehensive digital therapeutics solution that leverages artificial intelligence and machine learning to provide personalized and engaging patient experiences.

Please visit <https://lyfe.in/> for more information.

Follow us on LinkedIn: <https://www.linkedin.com/company/lupin-digital-health/>

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 8.7% of its revenue in research and development in FY22.

Lupin has 15 manufacturing sites, 7 research centres, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: <https://twitter.com/LupinGlobal> | LinkedIn: <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>

For further information or queries please contact –

Shweta Munjal

Vice President & Global Head – Corporate Communications

Email: shwetamunjal@lupin.com